



vTv Therapeutics to Present at the 8th Clinical Trials on Alzheimer's Disease (CTAD) Conference

10/22/15

HIGH POINT, N.C.--(BUSINESS WIRE)--Oct. 22, 2015-- vTv Therapeutics Inc. (Nasdaq:VTVT), a clinical-stage biopharmaceutical company engaged in the discovery and development of new orally administered treatments for Alzheimer's disease and diabetes, today announced that Dr. Marwan Sabbagh from the Barrow Neurological Institute, Principal Investigator for the ongoing Phase 3 Steadfast trial, will be presenting an evaluation of the Phase 2b safety study of azeliragon 20 mg/day and 5 mg/day in support of Phase 3 dose selection at the 8th Clinical Trials on Alzheimer's Disease (CTAD) conference. The oral presentation will take place on Friday, November 6 in Barcelona, Spain at 11:45 am CET (5:45 am EST).

About vTv Therapeutics Inc.

vTv Therapeutics Inc. is a clinical-stage biopharmaceutical company engaged in the discovery and development of orally administered small molecule drug candidates to fill significant unmet medical needs. vTv has a pipeline of clinical drug candidates led by programs for the treatment of Alzheimer's disease and type 2 diabetes as well as treatment of inflammatory disorders and the prevention of muscle weakness.

View source version on businesswire.com: <http://www.businesswire.com/news/home/20151022005151/en/>

Source: vTv Therapeutics Inc.

Investors

The Trout Group

Josh Barer, 646-378-2948

jbarer@troutgroup.com

or

Media

BMC Communications

Brad Miles, 646-513-3125

bmiles@bmccommunications.com